Ann: Update - Investment Conference Presentation, page-9

re: Ann: Update - Investment Conference Pres... Some info on ATL1101 from ANP website:

"The Company has previously announced that it had commenced a collaborative research programme with one of the world’s leading researchers in the field of prostate cancer, Professor Martin Gleave, Distinguished Professor, Department of Urological Sciences, University of British Columbia and Director of The Prostate Centre at Vancouver General Hospital, to examine the potential of ATL1101 in mouse models of human prostate cancer. Tthe Company announced positive results from its preclinical research study into the effects of ATL1101 on human prostate tumour growth. The key findings were that ATL1101 injections significantly suppressed the growth of the human tumours and slowed down their transition to the most dangerous form of prostate cancer, castration-resistant prostate cancer (CRPC). The Company reported further positive results from its collaborative preclinical research studies on the therapeutic potential of ATL1101 in prostate cancer. In experimental models, ATL1101 treatment significantly enhanced the tumour-suppressive effect of the cancer drug paclitaxel. Prostate tumour volume was halved after 5 weeks of paclitaxel/ATL1101 combination treatment, compared with control paclitaxel-treated mice and that even in prostate cancer cells that were resistant to the growth suppressive effects of the taxane chemotherapy drug paclitaxel, ATL1101 treatment was still able to suppress tumour cell growth. The resistant cancer cells’ sensitivity to paclitaxel was also enhanced after ATL1101 treatment. Resistance to the cytotoxic effects of taxane drugs is a major issue in the management of castrate resistant prostate cancer (CRPC) and other cancers.

Prostate cancer is the second most frequently diagnosed cancer in men after skin cancer. It is estimated there will be 218,890 new cases diagnosed in the U.S. this year. Around 1 in 6 men will develop prostate cancer, a third to a half of whom will recur after local treatment and risk progression to metastatic prostate cancer. Metastatic disease invariably progresses to hormone refractory prostate cancer (HRPC) if given enough time. Treatment options are limited for HRPC, and prognosis is poor. There is a pressing need for the development of new treatments."